Levothyroxine replacement therapy in patients with subclinical hypothyroidism and coronary artery disease.

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Valentin V FadeyevGalina Melnichenko

Abstract

To assess the potential benefits and risks associated with levothyroxine (LT4) therapy in patients with subclinical hypothyroidism (SH) and concomitant coronary artery disease (CAD). We enrolled 33 patients (4 male and 29 female subjects) with SH and CAD in this study. The study cohort consisted of 2 groups: 19 patients who were randomly assigned to receive LT4 therapy, titrated to maintain a normal serum thyrotropin level (main group), and 14 patients who did not receive any LT4 replacement therapy (control group). Variables of the lipid profile and left ventricular diastolic function were measured and 24-hour electrocardiographic monitoring was performed before randomization and at 6-month follow-up. Medical therapy for the CAD remained unchanged throughout the 6-month study period. In the main group, no statistically significant differences were found in the lipids, variables of left ventricular diastolic function, and heart rate pattern between the hypothyroid and euthyroid states. Individual analysis revealed, however, that LT4 therapy was beneficial in terms of lipid abnormalities in those patients with lower body mass index, shorter history of CAD, and higher cholesterol levels at baseline. In the control group, we noted...Continue Reading

References

Dec 1, 1981·The Journal of Clinical Endocrinology and Metabolism·E C RidgwayF Maloof
Oct 1, 1995·Clinical Endocrinology·A W KungE D Janus
Jun 1, 1996·Journal of the American College of Cardiology·G I CohenA L Klein
Apr 1, 1997·Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography·C P AppletonJ K Oh
Jun 18, 1999·The Journal of Clinical Endocrinology and Metabolism·B BiondiL Saccà
Mar 10, 2001·The Journal of Clinical Endocrinology and Metabolism·F MonzaniE Ferrannini
Apr 5, 2002·The Journal of Clinical Endocrinology and Metabolism·Nadia CaraccioFabio Monzani
Dec 3, 2002·Annals of Internal Medicine·Bernadette BiondiSerafino Fazio
Jun 6, 2003·The Journal of Clinical Endocrinology and Metabolism·Anne R Cappola, Paul W Ladenson
Aug 2, 2003·American Heart Journal·Christie M Ballantyne, Ron C Hoogeveen
Jan 15, 2004·JAMA : the Journal of the American Medical Association·Martin I SurksNeil J Weissman
May 22, 2004·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Jul 9, 2004·The Journal of Clinical Endocrinology and Metabolism·Misa ImaizumiKatsumi Eguchi
Jul 14, 2004·Endocrine·Bernadette Biondi, Irwin Klein

❮ Previous
Next ❯

Citations

Nov 15, 2006·Endocrine Journal·Mehmet UzunluluAytekin Oguz
Apr 17, 2012·International Journal of Endocrinology·Mehmet GunduzMesut Ozkaya
Aug 2, 2019·Current Opinion in Endocrinology, Diabetes, and Obesity·Ladan MehranFereidoun Azizi
Jul 26, 2017·Methodist DeBakey Cardiovascular Journal·Maja UdovcicAbhishek Kansara
Jul 20, 2007·The Cochrane Database of Systematic Reviews·H C C E VillarA N Atallah

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.